Print PDF

Sheppard Mullin Represents Vigene Biosciences in $350M Sale to Charles River Laboratories


Sheppard Mullin advised Vigene Biosciences, a premier, U.S.-based gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions, in its agreement to be acquired by Charles River Laboratories International, Inc. (NYSE: CRL) for $350 million. 

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.  The transaction is expected to close in the beginning of the third quarter of 2021, subject to regulatory requirements and customary closing conditions.

The Sheppard Mullin team was led by partner Shon Glusky and included partners Leo Caseria and Dmitriy Chelnitsky, special counsel Malika Levarlet and associate Brian Egan.

Click here to read the press release.


Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.